written on 28.02.2014

BioNotebook: Valeant back to black in 4Q; Forest submits NDA; Sunesis, Inovio, Oncolytics raise cash; Anacor Phase III plan


Valeant turns a profit at year's end; Forest submits nebivolol/valsartan NDA; Sunesis, Inovio price offerings; Lincoln Park commits $26m to Oncolytics; and FDA signs off Anacor's Phase III plan.